Humanized monoclonal antibody targeting alpha4-beta1 integrin.
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin.
Natalizumab is used in the treatment of multiple sclerosis and Crohn’s disease. It is co-marketed by Biogen Idec and Élan as Tysabri, and was previously named Antegren.
Natalizumab is administered by intravenous infusion every 28 days.
The drug is believed to work by reducing the ability of inflammatory immune cells to attach to (...)
Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies
Therapeutical antibodies
monoclonal antibodies; Therapeutical antibody
-
natalizumab
12 June 2005 -
bortezomib
5 June 2005Wikipedia
Bortezomib (INN, PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans.
It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma.
In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
Actions
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion (...) -
mepolizumab
24 November 2004Mepolizumab is an anti-IL5 monoclonal antibody.
-
anti-IL5 monoclonal antibodies
24 November 2004Exemples
mepolizumab -
rituximab
17 November 2004WKP
Rituximab is a chimeric anti-CD20 monoclonal antibody.
Rituximab (trade names Rituxan and MabThera) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells.
Rituximab destroys B cells, and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and some autoimmune disorders. (...) -
cetuximab
24 September 2004Erbitux
Definition: Cetuximab (Erbitux) is a monoclonal antibody designed to bind specifically to EGFR and block certain growth factors from binding and signaling the cell to promote tumor cell growth, survival, and progression.
Indications
treatment of EGFR-expressing metastatic colorectal cancer
See also
EGFR
References
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P, Cayre A, Manceau (...)